Table 2.

Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations

nKRASBRAFPIK3CA
Prevalence/heterogeneity (%)Prevalence/heterogeneity (%)Prevalence/heterogeneity (%)
All tumors10041/87/121/5
Stage I/II4028/105/015/3
Stage III4053/1010/328/8
Stage IV2045/05/020/5

NOTE: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary tumors, as determined by analyzing and comparing samples from both tumor centers and invasion fronts. Data are stratified according to UICC tumor stage.